Skip to main content
. 2021 Sep 22;14:4881–4891. doi: 10.2147/JIR.S331579

Table 1.

Demographic and Clinical Characteristics of 615 Included Patients with Alopecia Areata

Variables AA with AD (n = 76) AA without AD (n = 539) P-value
Sex, n (%) 0.008*
 ● Male 15 (19.8) 188 (35)
 ● Female 61 (80.2) 351 (65)
Age at AA onset, year, mean (SD) 37.9 (11.1) 36.8 (10.7) 0.618
Age at AA onset, year, n (%) 0.737
 ● < 18 5 (6.6) 43 (8.0)
 ● 18–30 21 (27.6) 173 (32.1)
 ● 31–45 18 (23.7) 140 (26.0)
 ● 46–60 19 (25.0) 108 (20.0)
 ● > 60 13 (17.1) 75 (13.9)
Duration of disease, month, median (IQR) 8 (4.5–23.5) 5 (3–11) 0.09
Duration of disease, n (%) <0.001*
 ● < 1 year 43 (56.6) 419 (77.8)
 ● > 1 year 33 (43.4) 120 (22.2)
AA subtype, n (%) 0.192
 ● Patch-type AA 45 (59.2) 380 (70.5)
 ● Multiple AA 22 (28.9) 109 (20.3)
 ● AT/AU 8 (10.5) 39 (7.2)
 ● Ophiasis 1 (1.4) 11 (2.0)
Severity of AA (SALT score), n (%) 0.181
 ● 0–25% 51 (67.1) 409 (75.9)
 ● 26–50% 12 (15.8) 48 (8.9)
 ● 51–75% 5 (6.6) 42 (7.8)
 ● 76–100% 8 (10.5) 40 (7.4)
Body hair involvement, n (%) 6 (8.2) 16 (3.0) 0.031*
Nail abnormalities, n (%) 13 (17.1) 41 (7.6) 0.006*
Atopic diseases, n (%) 30 (39.4) 112 (20.7) <0.001*
Family history of AA, n (%) 2 (2.6) 22 (4.1) 0.541
Family history of AD, n (%) 6 (7.9) 19 (3.5) 0.071

Note: *Statistically significant.

Abbreviations: AA, alopecia areata; AD, autoimmune disease; AT/AU, alopecia totalis/alopecia universalis; IQR, interquartile range; SALT, Severity of Alopecia Tool; SD, standard deviation.